NCT06999187 - A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions

Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung CancerCervical CancerCastrate Resistant Prostate CancerPancreatic Ductal AdenocarcinomaHead-and-neck Squamous Cell CarcinomaEndometrial CancerOvarian CancerGastric CancerGastroesophageal-junction CancerUrothelial Carcinoma

Interventions

DRUG

DR-0202

DR-0202 is a bispecific antibody

Trial Locations (10)

22031

RECRUITING

Dren Investigational Site, Fairfax

28078

RECRUITING

Dren Investigational Site, Huntersville

29605

RECRUITING

Dren Investigational Site, Greenville

32827

RECRUITING

Dren Investigational Site, Orlando

34232

RECRUITING

Dren Investigational Site, Sarasota

73104

RECRUITING

Dren Investigational Site, Oklahoma City

75230

RECRUITING

Dren Investigational Site, Dallas

78229

RECRUITING

Dren Investigational Site, San Antonio

78758

RECRUITING

Dren Investigational Site, Austin

80218

RECRUITING

Dren Investigational Site, Denver